Video: Superheroes, Secret Identities & You| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: corticosteroids

Dermatology Patients on Corticosteroids May Not Receive Osteoporosis Screenings; Plus FDA Approves ZTLido

Michele B. Kaufman, PharmD, BCGP  |  March 28, 2018

A recent study found that dermatology patients taking long-term steroids are not always evaluated for steroid-induced osteoporosis…

Filed under:AnalgesicsConditionsDrug UpdatesOsteoarthritis and Bone Disorders Tagged with:CorticosteroidsDermatologyFDAOsteoporosisPainSteroidsU.S. Food and Drug Administration (FDA)ZTLido

Why Oral Corticosteroids Should Not be Used in Patients with Rheumatoid Arthritis

Anthony S. Russell, MA, MB, BCHIR  |  April 1, 2013

 Steroid use in patients with rheumatoid arthritis (RA) has been linked to higher mortality rates, greater rate of infections, more cases of pneumonia, and serious gastrointestinal events

Filed under:ConditionsDrug UpdatesRheumatoid Arthritis Tagged with:Oral CorticosteroidsRARheumatoid arthritisSteroid

Case Report: Giant Cell Arteritis Presenting with Scalp Necrosis

Jude Al Qaqaa, MD, Vladimir Falb, DO, & Kaitlyn Buzard, DO  |  July 10, 2025

Giant cell arteritis (GCA), is an inflammatory vasculitis that involves large- and mediumsized arteries, most commonly the cranial branches of the carotid artery.1 It is seen in individuals 50 years and older.1 The most typical manifestation is new-onset headache with scalp tenderness and jaw claudication. 2 The most feared complication associated with GCA is permanent…

Filed under:ConditionsVasculitis Tagged with:AAV FocusRheumarteritiscase reportCorticosteroidsGiant Cell Arteritisscalp necrosistemporal artery biopsytocilizumabVasculitisvision loss

Editor's Pick

Calcium Pyrophosphate Deposition Disease: The Great Mimic

Bryn Nelson, PhD  |  July 9, 2025

CPPD is notoriously difficult to diagnose due to its diverse presentations & uncertain etiology. Recent advances have helped rheumatologists better understand its risk factors, classify, diagnose & treat the condition.

Filed under:ConditionsGout and Crystalline ArthritisOsteoarthritis and Bone DisordersRheumatoid Arthritis Tagged with:arthrocentesiscalcium pyrophosphate deposition diseasechondrocalcinosisColchicineCorticosteroidscrystal arthritisGoutGout Resource CenterinflammationOsteoarthritispseudogoutRheumatoid arthritis

Rheuminations: Can We Now Control the Wolf?

Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS  |  June 1, 2025

Lupus has always had a reputation for being a wild, unrestrained and enigmatic entity. In fact, the very name lupus comes from the Latin word for wolf, a gift from our Roman predecessors who saw a resemblance between lupus rashes and a wolf’s bite. Given the limitations of immunology back then, it is an incredibly…

Filed under:ConditionsOpinionRheuminationsSystemic Lupus Erythematosus Tagged with:kidney diseaseLupus nephritis supplement

Trials Find Potential Treatments for SLE, Lupus Nephritis

Michele B. Kaufman, PharmD, BCGP  |  May 31, 2025

In summer 2024, two phase 3 studies were released with promising findings for the treatment of patients with systemic lupus erythematosus (SLE) and those with lupus nephritis. SLE Disease Activity Dapirolizumab pegol is a novel, investigational, Fc-free anti-CD40L agent for people living with moderate to severe SLE.1 The randomized, double-blind, parallel-group PHOENYCS GO trial (N=321)…

Filed under:ConditionsDrug UpdatesSystemic Lupus Erythematosus Tagged with:dapirolizumab pegolLupus nephritis supplementobinutuzumab

Belimumab Promising for Children with Lupus Nephritis

Michele B. Kaufman, PharmD, BCGP  |  May 31, 2025

In late July 2022, the U.S. Food & Drug Administration (FDA) approved belimumab (Benlysta) for the treatment of children with active lupus nephritis aged 5 to 17 years old receiving standard therapy.1 Despite recent advances in treatment options for patients with systemic lupus erythematosus (SLE), those with kidney involvement may develop endstage renal disease and…

Filed under:ConditionsDrug UpdatesPediatric ConditionsSystemic Lupus Erythematosus Tagged with:belimumabFDA approvalLupus nephritis supplementPediatric

The ACR Releases New Lupus Nephritis Guideline

Ruth Jessen Hickman, MD  |  May 31, 2025

At a session of ACR Convergence 2024, speakers shared key elements of the new guideline on the screening, treatment and overall management of lupus nephritis in children and adults.1 This guideline attempts to balance the risks of medication side effects with the important goal of preserving kidney function. This is the ACR’s first lupus guideline…

Filed under:ACR ConvergenceClinical Criteria/GuidelinesConditionsGuidanceMeeting ReportsSystemic Lupus Erythematosus Tagged with:GuidelinesLupus nephritis supplement

The Great Imitator: Updates on Sarcoidosis

Jason Liebowitz, MD, FACR  |  January 15, 2025

Michelle Sharp, MD, MHS, shared insights into the complexities of sarcoidosis, describing how she evaluates, diagnoses and treats patients.

Filed under:ConditionsEULAR/OtherMeeting ReportsOther Rheumatic Conditions Tagged with:neurosarcoidosispatient carepulmonary sarcoidosisSarcoidosis

Skin Matters: The Intersection of Dermatology & Rheumatology

Jason Liebowitz, MD, FACR  |  January 1, 2025

Jun Kang, MD, addressed the intersection of dermatology and rheumatology, describing the nuance necessary to accurately evaluate skin manifestations and differentiate multiple conditions.

Filed under:ConditionsEULAR/OtherMeeting ReportsMyositisSystemic Lupus Erythematosus Tagged with:cutaneous lupus erythematosus (CLE)Dermatologydermatomyositisneutrophilic dermatosesskinskin disease

  • 1
  • 2
  • 3
  • …
  • 44
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences